BNR

$17.02+0.03 (+0.18%)

Market OpenAs of Mar 17, 3:54 PM UTC

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$17.02
Potential Upside
5%
Whystock Fair Value$17.87
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Developm...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$183.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-9.92%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.67

Recent News

MarketBeat
Mar 12, 2026

Brenntag Q4 Earnings Call Highlights

Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed and volumes weakening notably in the second half. On the company’s full-year results call, management

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Barchart
Nov 26, 2025

This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jul 16, 2025

3 Promising Penny Stocks With Market Caps Over $40M

The U.S. stock market has been navigating a period of volatility, with major indices such as the Dow Jones Industrial Average and the S&P 500 experiencing fluctuations amid geopolitical tensions and economic policy discussions. Despite these broader market challenges, penny stocks remain an intriguing area for investors, representing smaller or newer companies that can offer potential value when backed by strong financials. In this context, we explore three penny stocks that exhibit financial...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
BNR Stock Analysis & Real-Time Data | Whystock